2GM
Dihydroergotamine
Created: | 2013-01-17 |
Last modified: | 2013-03-13 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 80 |
Chiral Atom Count | 7 |
Bond Count | 87 |
Aromatic Bond Count | 16 |
Chemical Component Summary | |
---|---|
Name | Dihydroergotamine |
Systematic Name (OpenEye OEToolkits) | n/a |
Formula | C33 H37 N5 O5 |
Molecular Weight | 583.677 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 12.01 | O=C6N7C(C(=O)N1CCCC1C7(O)OC6(NC(=O)C4CC5c2cccc3c2c(cn3)CC5N(C)C4)C)Cc8ccccc8 |
SMILES | CACTVS | 3.370 | CN1C[CH](C[CH]2[CH]1Cc3c[nH]c4cccc2c34)C(=O)N[C]5(C)O[C]6(O)[CH]7CCCN7C(=O)[CH](Cc8ccccc8)N6C5=O |
SMILES | OpenEye OEToolkits | 1.7.6 | CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)Cc4ccccc4)NC(=O)C5CC6c7cccc8c7c(c[nH]8)CC6N(C5)C |
Canonical SMILES | CACTVS | 3.370 | CN1C[C@@H](C[C@H]2[C@H]1Cc3c[nH]c4cccc2c34)C(=O)N[C@]5(C)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](Cc8ccccc8)N6C5=O |
Canonical SMILES | OpenEye OEToolkits | 1.7.6 | C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)Cc4ccccc4)NC(=O)[C@@H]5C[C@@H]6c7cccc8c7c(c[nH]8)C[C@H]6N(C5)C |
InChI | InChI | 1.03 | InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1 |
InChIKey | InChI | 1.03 | LUZRJRNZXALNLM-JGRZULCMSA-N |
Drug Info: DrugBank
DrugBank ID | DB00320 |
---|---|
Name | Dihydroergotamine |
Groups |
|
Description | A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines.[L38469] Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity.[A239569] The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product. |
Synonyms |
|
Brand Names |
|
Indication | Dihydroergotamine (DHE) in all formulations is indicated for the acute treatment of migraine with or without aura in adults.[L38459, L38464, L38469] As an injection, DHE is also indicated for the acute treatment of cluster headache episodes.[L38459] DHE is not indicated for migraine prevention or the management of hemiplegic or basilar migraine.[L38459, L38464, L38469] |
Categories |
|
ATC-Code |
|
CAS number | 511-12-6 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
5-hydroxytryptamine receptor 1B | MEEPGAQCAPPPPAGSETWVPQANLSSAPSQNCSAKDYIYQDSISLPWKV... | unknown | agonist |
5-hydroxytryptamine receptor 1D | MSPLNQSAEGLPQEASNRSLNATETSEAWDPRTLQALKISLAVVLSVITL... | unknown | agonist |
5-hydroxytryptamine receptor 1F | MDFLNSSDQNLTSEELLNRMPSKILVSLTLSGLALMTTTINSLVIAAIIV... | unknown | agonist |
D(2) dopamine receptor | MDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVF... | unknown | agonist |
Alpha-2A adrenergic receptor | MFRQEQPLAEGSFAPMGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLT... | unknown | agonist |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL1732 |
PubChem | 10531 |
ChEMBL | CHEMBL1732 |
ChEBI | CHEBI:4562 |
CCDC/CSD | HERGOM |